Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Disease Awareness Information: The Xiaflex Dupuytren's Dilemma

This article was originally published in RPM Report

Executive Summary

Is FDA trying effectively to ban the practice of providing disease awareness information in promotoional materials? A recent letter to Auxilium on promotional materials for the company's drug for Dupuytren Disease (Xiaflex) suggests FDA is still looking closely at how companies describe disease states compared to a product's labeled indications.

You may also be interested in...



FDA Overreaches in Jurisdictional Power Grab

Letter to Dysport clinical investigator claims promotional violations in magazine interviews. Do clinical investigators really sign away their right to free speech when they conduct a clinical trial for a drug company?

No Fault? Not Quite

An HHS departmental appeals board decision finds Purdue executives at fault despite plea and convictions based solely on the Dotterweich and Park doctrines

Is FDA Above the Law?

The Food and Drug Administration is increasingly replacing rulemaking with guidance. The outcome of two legal cases indicates how that trend may be undercutting the administration's message of transparency.

Topics

UsernamePublicRestriction

Register

ID1125791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel